Acrux Limited (ARUXF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 5.68 Million AUD | 23.93% |
| 2023 | 4.58 Million AUD | -11.95% |
| 2022 | 5.21 Million AUD | 7.33% |
| 2021 | 4.85 Million AUD | -2.63% |
| 2020 | 4.98 Million AUD | 99.72% |
| 2019 | 2.49 Million AUD | -0.87% |
| 2018 | 2.51 Million AUD | -25.5% |
| 2017 | 3.38 Million AUD | -64.34% |
| 2016 | 9.48 Million AUD | 20.48% |
| 2015 | 7.87 Million AUD | -29.51% |
| 2014 | 11.16 Million AUD | 81.76% |
| 2013 | 6.14 Million AUD | 13.83% |
| 2012 | 5.39 Million AUD | -59.38% |
| 2011 | 13.28 Million AUD | 323.57% |
| 2010 | 3.13 Million AUD | -15.86% |
| 2009 | 3.72 Million AUD | 18.02% |
| 2008 | 3.15 Million AUD | 48.75% |
| 2007 | 2.12 Million AUD | -19.92% |
| 2006 | 2.65 Million AUD | 64.47% |
| 2005 | 1.61 Million AUD | 19.52% |
| 2004 | 1.34 Million AUD | 14.18% |
| 2003 | 1.18 Million AUD | 35.69% |
| 2002 | 870.46 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 6.67 Million AUD | 45.52% |
| 2024 Q2 | 6.37 Million AUD | 38.98% |
| 2024 Q4 | 5.68 Million AUD | -10.83% |
| 2023 Q2 | 4.38 Million AUD | -15.87% |
| 2023 Q4 | 4.58 Million AUD | 4.65% |
| 2023 FY | 4.58 Million AUD | -11.95% |
| 2022 FY | 5.21 Million AUD | 7.33% |
| 2022 Q2 | 4.01 Million AUD | -17.36% |
| 2022 Q4 | 5.21 Million AUD | 29.88% |
| 2021 Q2 | 5.63 Million AUD | 13.01% |
| 2021 FY | 4.85 Million AUD | -2.63% |
| 2021 Q4 | 4.85 Million AUD | -13.84% |
| 2020 Q2 | 4.44 Million AUD | 78.09% |
| 2020 Q4 | 4.98 Million AUD | 12.14% |
| 2020 FY | 4.98 Million AUD | 99.72% |
| 2019 Q2 | 1.82 Million AUD | -27.43% |
| 2019 Q4 | 2.49 Million AUD | 36.6% |
| 2019 FY | 2.49 Million AUD | -0.87% |
| 2018 Q2 | 1.82 Million AUD | -46.14% |
| 2018 FY | 2.51 Million AUD | -25.5% |
| 2018 Q4 | 2.51 Million AUD | 38.33% |
| 2017 Q4 | 3.38 Million AUD | -30.1% |
| 2017 FY | 3.38 Million AUD | -64.34% |
| 2017 Q2 | 4.83 Million AUD | -48.99% |
| 2016 Q4 | 9.48 Million AUD | 87.39% |
| 2016 FY | 9.48 Million AUD | 20.48% |
| 2016 Q2 | 5.06 Million AUD | -35.71% |
| 2015 Q4 | 7.87 Million AUD | 81.29% |
| 2015 FY | 7.87 Million AUD | -29.51% |
| 2015 Q2 | 4.34 Million AUD | -61.12% |
| 2014 Q2 | 13.16 Million AUD | 114.26% |
| 2014 FY | 11.16 Million AUD | 81.76% |
| 2014 Q4 | 11.16 Million AUD | -15.17% |
| 2013 Q2 | 1.24 Million AUD | -76.98% |
| 2013 FY | 6.14 Million AUD | 13.83% |
| 2013 Q4 | 6.14 Million AUD | 394.52% |
| 2012 FY | 5.39 Million AUD | -59.38% |
| 2012 Q4 | 5.39 Million AUD | 0.0% |
| 2011 FY | 13.28 Million AUD | 323.57% |
| 2011 Q4 | 13.28 Million AUD | 0.0% |
| 2010 Q4 | 3.13 Million AUD | 0.0% |
| 2010 FY | 3.13 Million AUD | -15.86% |
| 2009 Q4 | 3.72 Million AUD | 0.0% |
| 2009 FY | 3.72 Million AUD | 18.02% |
| 2008 Q4 | 3.15 Million AUD | 0.0% |
| 2008 FY | 3.15 Million AUD | 48.75% |
| 2007 FY | 2.12 Million AUD | -19.92% |
| 2007 Q4 | 2.12 Million AUD | 0.0% |
| 2006 FY | 2.65 Million AUD | 64.47% |
| 2006 Q4 | 2.65 Million AUD | 0.0% |
| 2005 Q4 | 1.61 Million AUD | 0.0% |
| 2005 FY | 1.61 Million AUD | 19.52% |
| 2004 FY | 1.34 Million AUD | 14.18% |
| 2004 Q4 | 1.34 Million AUD | 0.0% |
| 2003 FY | 1.18 Million AUD | 35.69% |
| 2002 FY | 870.46 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 89.331% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 40.649% |
| SQZ Biotechnologies Company | 50.03 Million USD | 88.635% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.153% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 90.363% |
| Mesoblast Limited | 188.44 Million USD | 96.982% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -47.66% |
| Genus plc | 485 Million USD | 98.827% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 2.664% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -126.004% |
| Marizyme, Inc. | 26.67 Million USD | 78.681% |
| ContraFect Corporation | 32.53 Million USD | 82.518% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -49.658% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -187.033% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -48.577% |
| Intellipharmaceutics International Inc. | 12 Million USD | 52.643% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 51.716% |
| MultiCell Technologies, Inc. | 1617.67 USD | -351455.014% |
| Accustem Sciences Inc. | 1.07 Million USD | -426.945% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.654% |
| EV Biologics, Inc. | 2.11 Million USD | -168.88% |
| Q BioMed Inc. | 8.13 Million USD | 30.074% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.143% |
| Neon Bloom, Inc. | 1.22 Million USD | -363.786% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -10.512% |
| Biomind Labs Inc. | 1.49 Million USD | -279.484% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 97.67% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 69.098% |
| Skye Bioscience, Inc. | 14.07 Million USD | 59.587% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -182.917% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3902.252% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 39.921% |
| IMV Inc. | 37.93 Million USD | 85.008% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2727.721% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 1.024% |
| GB Sciences, Inc. | 5.41 Million USD | -4.974% |
| Alpha Cognition Inc. | 7.16 Million USD | 20.626% |
| HST Global, Inc. | 593.59 Thousand USD | -858.064% |
| CSL Limited | 18.62 Billion USD | 99.969% |
| Halberd Corporation | 728.71 Thousand USD | -680.411% |
| Enzolytics Inc. | 365.26 Million USD | 98.443% |
| Resverlogix Corp. | 67.39 Million USD | 91.562% |
| Affymax, Inc. | 8.87 Million USD | 35.892% |
| SYBLEU INC | 681.41 Thousand USD | -734.589% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -578.047% |
| argenx SE | 444.95 Million USD | 98.722% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.409% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -231.797% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 52.223% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -55.164% |
| AVAX Technologies, Inc. | 3.99 Million USD | -42.398% |
| Zenith Capital Corp. | 27.56 Thousand USD | -20528.242% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.571% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2282.948% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -52.291% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -735.299% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.21% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 37.106% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -8397.064% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -296.621% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 88.686% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -109.725% |
| BioStem Technologies, Inc. | 15.9 Million USD | 64.243% |
| ONE Bio Corp. | 27.49 Million USD | 79.317% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1123.803% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -20630.507% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -351.638% |
| Agentix Corp. | 2.51 Million USD | -126.524% |
| LadRx Corporation | 2.2 Million USD | -158.438% |
| Cell Source, Inc. | 15.8 Million USD | 64.022% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -12623.734% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4.203% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4.203% |
| NovAccess Global Inc. | 7.86 Million USD | 27.653% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 77.019% |
| Itoco Inc. | 1.65 Million USD | -244.01% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -177.203% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 5.984% |
| Kadimastem Ltd | 3.5 Million USD | -62.26% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1249.011% |
| CytoDyn Inc. | 127.89 Million USD | 95.553% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -13505.589% |
| Mobile Lads Corp. | 1.31 Million USD | -332.966% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -263.067% |
| Qrons Inc. | 1.48 Million USD | -282.008% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 48.512% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -603.146% |
| Rebus Holdings, Inc. | 5.24 Million USD | -8.489% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 6.8% |
| International Stem Cell Corporation | 5.27 Million USD | -7.77% |
| Bioxytran, Inc. | 3.24 Million USD | -75.012% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -808.744% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -23.172% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 86.128% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 74.458% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -180.786% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -3.815% |
| Neutra Corp. | 973.52 Thousand USD | -484.163% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 80.4% |
| PureTech Health plc | 125.58 Million USD | 95.472% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -51.366% |
| IXICO plc | 1.9 Million USD | -199.27% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 72.298% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.496% |
| CSL Limited | 18.62 Billion USD | 99.969% |
| Cellectis S.A. | 249.36 Million USD | 97.719% |